- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07948967
Physiological Associations and Prognostic Discrimination of an EIT-Derived Flow Index During Noninvasive Ventilation (NIV-EFI)
Physiological Associations and Prognostic Discrimination of an Electrical Impedance Tomography-Derived Flow Index During Noninvasive Ventilation: A Multicenter Prospective Cohort With a Nested Physiological Substudy
This is a multicenter prospective observational cohort study with a nested physiological substudy. It aims to enroll 220 adults with acute hypoxemic respiratory failure (AHRF) initiating mask noninvasive ventilation (NIV). The study will assess the measurement feasibility, physiological associations, and early prognostic discrimination of the electrical impedance tomography (EIT)-derived flow index (EFI) during NIV. The primary objective is to estimate how well pre-landmark T1 EFI discriminates the risk of endotracheal intubation or all-cause death through 48 hours. A nested physiological substudy (n=20) will evaluate the within-patient association between EFI and airway occlusion pressure across fixed pressure support (PS) levels (5, 10, and 15 cmH2O). Clinical management remains independent of study measurements.
Visão geral do estudo
Status
Descrição detalhada
This study will enroll adults with AHRF for whom the treating team has decided to initiate mask NIV. The main cohort (n=220) is observational. EIT data will be acquired at baseline (T0), 60-120 min (T1), 20-24 h (T2), and 42-48 h (T3). The primary predictor is the median EFI across valid breaths during T1 (before the 2-h landmark). The primary endpoint is the first occurrence of endotracheal intubation or all-cause death after 2 h and through 48 h among patients eligible at the 2-h landmark.
A nested, non-randomized physiological substudy (n=20) will be conducted after T1. After confirming safety and obtaining separate informed consent, patients will undergo a fixed sequence of brief pressure support steps (PS 5, 10, and 15 cmH2O) with EPAP and FiO2 held at clinical settings. Brief airway occlusions will be performed at each level to measure occlusion pressure (Pocc and P0.1). The substudy aims to estimate the within-patient association between EFI and |Pocc|. The study was approved by the Ethics Committee of Ruijin Hospital (Approval No. 2026846). Written informed consent is obtained from all participants (and separate consent for the substudy).
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Rui Zhang
- Número de telefone: +86-18801119381
- E-mail: ccmzhangrui@foxmail.com
Locais de estudo
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200025
- Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
Contato:
- Yun Feng
- Número de telefone: +86-17321113771
- E-mail: fy11697@rjh.com.cn
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Adults (aged 18 years or older) with acute hypoxemic respiratory failure (AHRF) for whom the treating clinical team has decided to initiate mask noninvasive ventilation (NIV) in the intensive care unit. A subset of stable patients will participate in the nested physiological sub-study.
Descrição
Inclusion Criteria:
- Age 18 years or older.
- Clinical diagnosis of AHRF and a decision to initiate NIV through an oronasal or full-face mask (PaO2/FiO2 ≤ 300 mmHg or FiO2 ≥ 0.40 to maintain oxygenation target).
- Consent and enrollment completed before NIV begins or within 60 min of initiation.
- Written informed consent from the patient or authorized representative (separate consent for substudy).
Exclusion Criteria:
- Immediate clinical need for endotracheal intubation or clear contraindication to NIV.
- Facial trauma, severe chest-wall skin injury, or incisions preventing safe placement of EIT belt.
- Contraindication in EIT device manual (e.g., incompatible implanted device).
- Pregnancy or lactation.
- Baseline do-not-intubate (DNI) decision or comfort measures only.
- Inability to obtain valid consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Main Cohort
Adults with AHRF initiating mask NIV (n=220). Observational; T1 EFI is evaluated for discriminating 48-hour intubation or death. |
Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team. Continuous EIT monitoring to derive the dimensionless flow index (EFI). |
|
Nested Physiological Substudy
A subset of the main cohort (n=20). Consenting patients undergo brief, sequential pressure support (PS) adjustments (5, 10, 15 cmH2O) and airway occlusions to measure EFI and |Pocc| associations. |
Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team. Continuous EIT monitoring to derive the dimensionless flow index (EFI). Protocol-specified PS steps (5, 10, 15 cmH2O) and device-supported airway occlusions performed in the physiological substudy. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Endotracheal Intubation or All-Cause Death (2h to 48h)
Prazo: After 2 hours through 48 hours.
|
The first occurrence of endotracheal intubation or all-cause death after 2 hours and through 48 hours from NIV initiation, among patients alive and still receiving NIV at the 2-hour landmark.Unit of Measure: Proportion of participants (or Event count) |
After 2 hours through 48 hours.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Discrimination Performance (AUC) of T1 EFI
Prazo: Within 72 hours
|
Area under the receiver operating characteristic curve (AUC) of the pre-landmark T1 EFI for predicting the primary composite endpoint.Unit of Measure: AUC (dimensionless, 0-1) |
Within 72 hours
|
|
Within-Patient Association between EFI and |Pocc|
Prazo: Within 2 to 6 hours after NIV initiation.
|
The within-patient slope of the association between EFI and the absolute magnitude of occlusion pressure (|Pocc|) across fixed pressure support levels in the physiological sub-study. Unit of Measure: cmH2O per unit of EFI |
Within 2 to 6 hours after NIV initiation.
|
|
Intubation or Death by Day 7
Prazo: Within day 7
|
ncidence of endotracheal intubation or all-cause mortality by day 7.Unit of Measure: Proportion of participants |
Within day 7
|
|
28-Day All-Cause Mortality
Prazo: within day 28
|
All-cause mortality rate at day 28.Unit of Measure: Proportion of participants |
within day 28
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2026846
- (2026) Lin Lun Shen No. 846 (Outro identificador: Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified analysis datasets may be shared on reasonable request for verification, subject to ethics approval.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .